Cargando…

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)

Despite the promise of targeted therapies, there remains an urgent need for effective treatment for esophageal cancer (EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs have significant problems of toxicity, safety, selectivity, efficacy and development of resistance. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Overholser, Jay, Ambegaokar, Kristen Henkins, Eze, Siobhan M., Sanabria-Figueroa, Eduardo, Nahta, Rita, Bekaii-Saab, Tanios, Kaumaya, Pravin T.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586465/ https://www.ncbi.nlm.nih.gov/pubmed/26350593 http://dx.doi.org/10.3390/vaccines3030519

Ejemplares similares

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
por: Kaumaya, Pravin T. P., et al.
Publicado: (2020)

A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)
por: Guo, Linlin, et al.
Publicado: (2022)

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo
por: Foy, Kevin C., et al.
Publicado: (2012)

Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines
por: Ozbay, Tuba, et al.
Publicado: (2011)

B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine
por: Kaumaya, Pravin TP
Publicado: (2020)

Possible role of the Ec peptide of IGF-1Ec in cartilage repair
por: Armakolas, Nikolaos, et al.
Publicado: (2016)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer
por: Foy, Kevin C., et al.
Publicado: (2012)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
por: Nahta, Rita
Publicado: (2012)

Correction to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048–1060
por: Foy, Kevin C., et al.
Publicado: (2013)

Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
por: Guo, Linlin, et al.
Publicado: (2022)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
por: Reddy, Tejaswini P., et al.
Publicado: (2020)

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2023)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

Direct analysis of HLA/HER-2 peptide epitopes
por: Patterson, Andrea, et al.
Publicado: (2013)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors
por: Armakolas, A., et al.
Publicado: (2018)

Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer
por: Alanazi, Ibrahim O., et al.
Publicado: (2021)

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

Peptide Based Imaging Agents for HER2 Imaging in Oncology
por: Ducharme, Maxwell, et al.
Publicado: (2020)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
por: Zhang, Shu, et al.
Publicado: (2016)

Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients
por: Wignarajah, Shayalini, et al.
Publicado: (2023)

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
por: Wang, Mengting, et al.
Publicado: (2022)

Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling
por: Peake, Bridgette F., et al.
Publicado: (2017)

Development of Peptide Nucleic Acid Probes for Detection of the HER2 Oncogene
por: Metaferia, Belhu, et al.
Publicado: (2013)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
por: Ducharme, Maxwell, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling
por: Peake, Bridgette F., et al.
Publicado: (2020)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
por: Corcoran, Claire, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jc5haegu8sod4ja8mh4no2qckk